Non-Hodgkin's lymphoma in systemic lupus erythematosus by Bernatsky, S et al.
doi:10.1136/ard.2004.034504 
 2005;64;1507-1509 Ann Rheum Dis
  
St Pierre and A Clarke 
Edworthy, S Barr, C Gordon, S-C Bae, J Sibley, K Steinsson, O Nived, G Sturfelt, Y
Cournoyer, A Zoma, S Manzi, E Ginzler, M Urowitz, D Gladman, P R Fortin, S 
S Bernatsky, R Ramsey-Goldman, R Rajan, J-F Boivin, L Joseph, S Lachance, D
  
 erythematosus
Non-Hodgkin’s lymphoma in systemic lupus
 http://ard.bmj.com/cgi/content/full/64/10/1507
Updated information and services can be found at: 
 These include:
 References
 http://ard.bmj.com/cgi/content/full/64/10/1507#otherarticles
11 online articles that cite this article can be accessed at: 
  
 http://ard.bmj.com/cgi/content/full/64/10/1507#BIBL
This article cites 27 articles, 5 of which can be accessed free at: 
Rapid responses
 http://ard.bmj.com/cgi/eletter-submit/64/10/1507
You can respond to this article at: 
  
 http://ard.bmj.com/cgi/content/full/64/10/1507#responses
One rapid response has been posted to this article, which you can access for free at:
 service
Email alerting
top right corner of the article 
Receive free email alerts when new articles cite this article - sign up in the box at the
Topic collections
 (225 articles) Systemic Lupus Erythematosus 
 (980 articles) Cancer:other 
  
Articles on similar topics can be found in the following collections 
 Notes   
 http://journals.bmj.com/cgi/reprintform
To order reprints of this article go to: 
 http://journals.bmj.com/subscriptions/
 go to: Annals of the Rheumatic DiseasesTo subscribe to 
 on 18 December 2007 ard.bmj.comDownloaded from 
CONCISE REPORT
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Background: Recent evidence supports an association
between systemic lupus erythematosus (SLE) and non-
Hodgkin’s lymphoma (NHL).
Objectives: To describe demographic factors, subtypes, and
survival of patients with SLE who develop NHL.
Methods: A multi-site cohort of 9547 subjects with definite
SLE was assembled. Subjects at each centre were linked to
regional tumour registries to determine cancer cases
occurring after SLE diagnosis. For the NHL cases ascertained,
descriptive statistics were calculated, and NHL subtype
frequency and median survival time of patients determined.
Results: 42 cases of NHL occurred in the patients with SLE
during the 76 948 patient-years of observation. The median
age of patients at NHL diagnosis was 57 years. Thirty six
(86%) of the 42 patients developing NHL were women,
reflecting the female predominance of the cohort. In the
patients, aggressive histological subtypes appeared to
predominate, with the most commonly identified NHL
subtype being diffuse large B cell (11 out of 21 cases for
which histological subtype was available). Twenty two of the
patients had died a median of 1.2 years after lymphoma
diagnosis.
Conclusions: These data suggest aggressive disease in
patients with SLE who develop NHL. Continuing work should
provide further insight into the patterns of presentation,
prognosis, and aetiology of NHL in SLE.
I
n the past three decades, data has accumulated about an
increased risk of lymphoma, particularly non-Hodgkin’s
lymphoma (NHL), in systemic lupus erythematosus
(SLE).1–3 The reasons for this increased risk are unknown.
In the general population, NHL risk is determined by various
factors, including age, sex, and race, among others.4–6 In
general, more aggressive lymphoma types can arise in
immunosuppressed states.7 Relatively aggressive subtypes
appear to dominate lymphomas seen in rheumatoid arthritis,
which, like SLE, is associated with an increased risk of NHL.8
In contrast, in primary Sjo¨gren’s syndrome (also associated
with NHL) the commonest lesions are low grade (indolent),
marginal zone lymphomas related to mucosa associated
lymphoid tissue (MALT).9
Little is known about the frequency of NHL subtypes in
SLE. This is unfortunate, because determining subtype
predominance in SLE might be an important step in
exploring pathogenic mechanisms for the association of
NHL and SLE. This has not been possible to date because of
the small absolute number of NHL cases in single centre
studies.
We recently completed a multi-site international cohort
study that calculated standardised incidence ratios for cancer
in SLE in comparison with the general population. The
standardised incidence ratio for NHL was 3.6 (95% con-
fidence interval (CI) 2.6 to 4.9),1 consistent with other
studies, although our estimates were more precise. The
objectives of the current paper are to report the subtype
distribution of NHL in this SLE cohort, and to describe
pertinent demographic factors (for example, age, sex, race) in
these subjects. We also provide some preliminary work on the
stage and survival of the patients with SLE in whom an NHL
occurred.
MATERIALS AND METHODS
We assembled a multi-site international cohort study
involving 23 clinical centres in Canada, America, the UK
(England and Scotland), Sweden, Iceland, and Korea.1 All
patients with definite SLE according to American College of
Rheumatology or clinical criteria were eligible.
Data were available on patient birth date and sex, dates of
SLE diagnosis and cohort entry, and vital status. Cases of
NHL occurring after SLE diagnosis were ascertained by
regional cancer registry linkage. For the observation interval,
we subtracted the later of two entry dates (beginning of
cancer registry observation interval or first visit to the
respective SLE clinic) from the earlier of two exit dates
(end date of tumour registry data or death). The calendar
time spanned 1958–2000.
We calculated descriptive statistics for demographics (age,
sex, race) for all patients with NHL occurring within the
observation interval, and the SLE duration at the time of NHL
diagnosis. We ascertained the frequency of histological
subtypes and tumour stage, where known. As well as
determining the median and mean survival times after NHL
diagnosis, we calculated the Kaplan-Meier estimate for the
5 year survival probability.
RESULTS
In total, 9547 patients with SLE were observed for a total of
76 948 patient-years.1 Forty two cases of NHL occurred
during the observation interval.
The mean age at the time of NHL diagnosis in our sample
was 55.3 years (SD 15.1, median 57, interquartile range 18).
Among the 42 NHL cases, 36 (86%) patients were women.
The majority of subjects who developed NHL were white
(n=20, 48%); the remainder were black (n=5, 12%), other
(one native North American, one Asian) or unknown (n=15,
36%). Average SLE duration at the time of NHL diagnosis was
6.7 years (SD 5.8, median 4.0, interquartile range 8).
For 21 of the NHL cases found on tumour registry linkage,
the subtype was not specified. The most common NHL type
among the remaining 21 cases was diffuse large B cell
(n=11, 52% of the cases of known subtype), with the
remainder being small lymphocytic (n=4, 19%), follicular
Abbreviations: CI, confidence interval; MALT, mucosa associated
lymphoid tissue; NHL, non-Hodgkin’s lymphoma; SLE, systemic lupus
erythematosus
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(n=3, 14%), and one each of Burkitt’s, peripheral T cell, and
MALT lymphoma.
In only 14/42 (33%) cases of NHL was staging information
available. Of these 14, five (36%) were localised disease, and
the remainder were advanced (two regionally spread, the
others widespread) stage.
Twenty two (52%) of the 42 cases had died a median of
1.2 years after lymphoma diagnosis. The remaining subjects
had survived for a median of 2.1 years. Of the 21 cases where
information on subtype was incomplete, nine subjects (43%
of these 21 cases) had died after a median survival of
0.5 years (mean (SD) 2.5 (2.9)). Of the 22 patients with SLE
and NHL who had died, information on specific cause of
death was available in 10 cases, the primary cause of death
being malignancy in all but one of these (in whom congestive
heart failure was the cause of death). After diagnosis of NHL,
the Kaplan-Meier estimate for the probability of survival to
5 years was 46.8% (95% CI 19.6 to 73.9).
DISCUSSION
In general, NHL is more common in men7; indeed the
percentage of men among our subjects who developed NHL
(14%) was slightly higher than the percentage of men in the
entire cohort (10%).1 NHL incidence is also highest among
white subjects7; this was possibly reflected in our sample
because the proportion of white subjects among the NHL
cases (74% of all cases where race was known) was slightly
higher than the proportion of white subjects in the entire
cohort (just under 70%).10
‘‘Anticipation’’ is a term describing the phenomenon
whereby subjects who have strong genetic determinants of
cancer present for investigation at an earlier age than the
norm.11 For the general population, the median age at NHL
diagnosis is 60–65 years.7 The slightly lower median age at
time of cancer diagnosis for the patients with NHL in our
cohort may be due to an overall younger age distribution of
subjects with SLE than in the general population. Thus, one
cannot necessarily interpret our findings as suggestive of a
genetic basis for an association between NHL and SLE.
NHL can be divided into two general prognostic groups:
indolent lymphomas and more aggressive (intermediate or
high grade) lymphomas.7 Of the 21 NHL of known type
occurring during the observation interval, only nine were
probably indolent, with the remaining being more aggressive
(diffuse large B cell and Burkitt’s) lymphoma.
The diffuse large B cell subtype makes up about 30% of all
NHL lymphomas in the general population,7 but represented
more than half of the NHL lymphomas of known cell type in
our sample (a difference of 22.4%, 95% CI 2.2 to 41.8%).
Information about tumour subtype was inadequate for many
of the cases. However, the median survival time of patients
with NHL of unknown subtype was 2.1 years, which is in
keeping with more aggressive kinds of NHL. However,
because diffuse large B cell lymphomas may arise from other
lesions,12 it is possible that some of the diffuse large B cell
lymphomas seen in our sample arose from previously
unrecognised more indolent disease.
Only one of the patients with SLE observed developed a
MALT lymphoma during the study interval. This is of
interest, because some speculate that the increased NHL risk
in SLE might relate to overlap with Sjo¨gren’s syndrome.
Given our findings, it appears unlikely that identical
pathological processes are occurring in the cases of cancer
that develop in patients with Sjo¨gren’s syndrome and SLE.
The genetic abnormalities underlying the association
between SLE and NHL are unknown. An important feature
of NHL is the presence of chromosomal abnormalities
(table 1), such as translocations in which an oncogene is
juxtaposed next to a gene important for immune cell
function.7 These chromosomal abnormalities may represent
common pathways linking SLE and lymphoproliferative
malignancies. Specifically, the same oncogenic factors impli-
cated in NHL may be important in SLE pathogenesis, where
uncontrolled lymphocyte proliferation also occurs.
We are unable to comment about specific translocations in
the NHL cases that arose in our subjects. For the present, a
reasonable hypothesis is that uncontrolled lymphocyte
activity in active SLE leads to chromosomal translocations
that allow malignant transformation.13 However, the effect of
immunosuppressive agents and viral exposures (such as the
Epstein-Barr virus are also of interest. These factors are
currently under study.
The likelihood of extrinsic exposures (such as drugs)
would presumably increase with SLE duration; intrinsic
immunopathology might also vary with time. Given this, it
would be interesting to know whether the histological
subtypes differ for those patients who developed NHL early
(versus later) in the course of SLE. Unfortunately, the
relatively small number of NHL cases hampered our
examination of this issue. We note that of the 21 cases
where NHL subtype was known, two had occurred within a
year of the SLE diagnosis; one of these was a diffuse large B
cell lymphoma. In the remaining 19 cases where NHL
subtype was known (all occurring more than a year after
SLE diagnosis), 10 (53%) were diffuse large B cell.
In general, with current treatment, median survival for
NHL in the general population exceeds 5 years14; this rate has
been relatively stable for the past three decades, which is
when the NHL cases in our cohort occurred. Median survival
for indolent NHL types is estimated at 8–10 years. Twenty
two of our 42 cases had died after a median of 1.2 years. The
remaining subjects had survived to a median of 2.1 years.
Table 1 Reported chromosomal abnormalities seen in specific subtypes of NHL
Translocation
Associated
histology
Oncogene
affected
Molecular
events Comments
t(3;16)
(q27;p11)
Diffuse large B
cell (DLBC)
bcl-6 Lymphocyte
proliferation
16–35% of DLBC and (13% of follicular NHL
have bcl-6 translocation 15% of DLBC have
bcl-1 translocation Mutations of the p53
suppressor gene may also be seen in DLBC
(especially those that transformed from FL)
t(14;18)
(q32;q21)
Follicular (FL) bcl-2 Apoptosis
inhibition
80–90% of FL, and 6–30% of DLBC have bcl-2
translocation (These DLBC may represent
transformation from FL)
t(8:14)
(q24:q32)
Burkitt’s c-myc Lymphocyte
proliferation
Translocation of t(8:14) and others involving c-
myc present to a lesser extent in DLBC (,10%).
t(1;14)
(p22;q32)
Marginal zone
(MALT)
bcl-10 Apoptosis
inhibition
Another translocation, t(15;16) (p21,q21) in
,25% of MALT
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This suggests that patients with SLE who develop NHL do not
fare as well as most patients with NHL. This is particularly
interesting given that the majority of the patients with NHL
in our sample were young, white women, which are
traditionally indicators of good prognosis.
We do not have information about the cancer treatment
given to the patients with SLE who developed NHL, or data
about their response and relapse rates after treatment.
However, we are embarking upon a review of the pathology
and clinical factors (including prognostic factors at presenta-
tion (particularly stage), treatment, response, and relapse) of
the NHL cases that arose in our SLE sample.
If more aggressive tumour types or late stage of presenta-
tion are more common in SLE, these might lead to a lower
than expected survival. Also, some therapeutic measures may
be inappropriately withheld from patients with SLE who
develop cancer.15 Other possible reasons for our observed data
include decreased survival related to SLE comorbidity.
In summary, we have completed the most comprehensive
assessment to date of NHL cases within a large SLE cohort.
These data suggest more aggressive disease in patients with
SLE who develop NHL compared with the general population.
Continuing work should provide much needed insight into
the aetiology of NHL in SLE.
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